Trial site
Banner McKee Medical Center
Loveland, Colorado 80539, United StatesNot linked to an institution yet
- 3running trials
- 15closed trials
The trials here
What the 18 trials at this site are about, from their registry records.
- Phase
- Phase 26 trials
- Phase 36 trials
- Phase 2/34 trials
- Phase 1/21 trial
- Status
- Completed14 trials
- Active, not recruiting3 trials
- Terminated1 trial
- Lead sponsor
- National Cancer Institute (NCI)13 trials
- Alliance for Clinical Trials in Oncology1 trial
- Children's Oncology Group1 trial
- ECOG-ACRIN Cancer Research Group1 trial
- Galera Therapeutics, Inc.1 trial
- and 1 more
Closed trials
Terminated
Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC
NCT04476797· Phase 1/2· Galera Therapeutics, Inc.· Source
Completed
Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer
NCT03602586· Phase 2· National Cancer Institute (NCI)· Source
Completed
Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer
NCT03382561· Phase 2· National Cancer Institute (NCI)· Source
Completed
Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin
NCT03258554· Phase 2/3· National Cancer Institute (NCI)· Source
Completed
Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
NCT03092674· Phase 2/3· National Cancer Institute (NCI)· Source
Completed
Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia
NCT03204916· Children's Oncology Group· Source
Completed
Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma
NCT03033576· Phase 2· National Cancer Institute (NCI)· Source
Completed
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
NCT02595905· Phase 2· National Cancer Institute (NCI)· Source
Completed
Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT02498600· Phase 2· National Cancer Institute (NCI)· Source
Completed
Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
NCT02101788· Phase 2/3· National Cancer Institute (NCI)· Source
Completed
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
NCT02003209· Phase 3· National Cancer Institute (NCI)· Source
Completed
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery
NCT01013649· Phase 3· National Cancer Institute (NCI)· Source
Completed
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
NCT00861705· Phase 2· National Cancer Institute (NCI)· Source
Completed
Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer
NCT00601900· Phase 3· National Cancer Institute (NCI)· Source
Completed
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery
NCT00324805· Phase 3· National Cancer Institute (NCI)· Source
Report an error